Jacobs Levy Equity Management
ATOS icon

Jacobs Levy Equity Management’s Atossa Therapeutics ATOS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,886
Closed -$618K – 960
2025
Q4 		$618K Buy
+69,886
New +$884K ﹤0.01% 766

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jacobs Levy Equity Management's ATOS Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 69,886 shares — an estimated $618K sold.

Jacobs Levy Equity Management first reported a position in ATOS in Q4 2025 and held it in 1 quarter. The position peaked at $618K in Q4 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 69,886 Atossa Therapeutics shares in Q1 2026, an estimated $618K.
  • Jacobs Levy Equity Management first reported a position in Atossa Therapeutics in Q4 2025 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Atossa Therapeutics position peaked at $618K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.